Prognostic Impact of Pretherapeutic FDG-PET in Localized Anal Cancer.

FDG-PET anal cancer metabolic tumour volume prognosis

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
09 Jun 2020
Historique:
received: 27 03 2020
revised: 29 05 2020
accepted: 06 06 2020
entrez: 13 6 2020
pubmed: 13 6 2020
medline: 13 6 2020
Statut: epublish

Résumé

Due to the heterogeneity of tumour mass segmentation methods and lack of consensus, our study evaluated the prognostic value of pretherapeutic positron emission tomography with fluorodeoxyglucose (FDG-PET) metabolic parameters using different segmentation methods in patients with localized anal squamous cell carcinoma (SCC). Eighty-one patients with FDG-PET before radiochemotherapy were retrospectively analyzed. Semiquantitative data were measured with three fixed thresholds (35%, 41% and 50% of Maximum Standardized Uptake Value (SUVmax)) and four segmentation methods based on iterative approaches (Black, Adaptive, Nestle and Fitting). Metabolic volumes of primary anal tumour (P-MTV) and total tumour load (T-MTV: P-MTV+ lymph node MTV) were calculated. The primary endpoint was event-free survival (EFS). Seven multivariate models were created to compare FDG-PET tumour volumes prognostic impact. For all segmentation thresholds, PET metabolic volume parameters were independent prognostic factor and T-MTV variable was consistently better associated with EFS than P-MTV. Patient's sex was an independent variable and significantly correlated with EFS. With fixed threshold segmentation methods, 35% of SUVmax threshold seemed better correlated with EFS and the best cut-off for discrimination between a low and high risk of event occurrence was 40 cm

Identifiants

pubmed: 32527039
pii: cancers12061512
doi: 10.3390/cancers12061512
pmc: PMC7352672
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

N Engl J Med. 2000 Mar 16;342(11):792-800
pubmed: 10717015
Radiother Oncol. 2008 Jun;87(3):376-82
pubmed: 18453023
Int J Radiat Oncol Biol Phys. 2013 Nov 15;87(4):638-45
pubmed: 24035327
Cancer. 1983 May 15;51(10):1830-7
pubmed: 6831349
Int J Radiat Oncol Biol Phys. 2012 May 1;83(1):134-41
pubmed: 22000745
J Natl Compr Canc Netw. 2012 Apr;10(4):449-54
pubmed: 22491045
Radiol Med. 2016 Jan;121(1):54-9
pubmed: 26126968
Phys Med Biol. 2009 Nov 21;54(22):6901-16
pubmed: 19864698
J Nucl Med. 2005 Aug;46(8):1342-8
pubmed: 16085592
Int J Radiat Oncol Biol Phys. 2012 Sep 1;84(1):66-72
pubmed: 22592047
Phys Med Biol. 2012 Sep 7;57(17):5381-97
pubmed: 22864012
Int J Colorectal Dis. 2011 Feb;26(2):201-10
pubmed: 21061012
Hematol Oncol Clin North Am. 2012 Dec;26(6):1315-50
pubmed: 23116582
Int J Radiat Oncol Biol Phys. 1994 Apr 30;29(1):17-23
pubmed: 8175426
Br J Radiol. 2019 May;92(1097):20181006
pubmed: 30810343
Eur J Nucl Med Mol Imaging. 2017 Jan;44(1):63-70
pubmed: 27503193
Int J Radiat Oncol Biol Phys. 2004 Nov 15;60(4):1272-82
pubmed: 15519800
Int J Radiat Oncol Biol Phys. 1989 Dec;17(6):1141-51
pubmed: 2599902
Radiother Oncol. 2010 Jun;95(3):288-91
pubmed: 20231040
Int J Radiat Oncol Biol Phys. 2006 Jul 1;65(3):720-5
pubmed: 16626889
Eur J Radiol. 2016 Aug;85(8):1390-4
pubmed: 27423677
Lancet. 1996 Oct 19;348(9034):1049-54
pubmed: 8874455
Br J Radiol. 2017 Dec;90(1080):20170370
pubmed: 28972796
Ann Surg Oncol. 2015 Oct;22(11):3574-81
pubmed: 25652048
Ann Oncol. 2014 Sep;25 Suppl 3:iii10-20
pubmed: 25001200
Dig Liver Dis. 2017 Aug;49(8):831-840
pubmed: 28610905
Ann Oncol. 2012 Aug;23(8):2078-2082
pubmed: 22294527
Eur J Nucl Med Mol Imaging. 2019 Dec;46(13):2790-2799
pubmed: 31482428
Dis Colon Rectum. 1987 May;30(5):324-33
pubmed: 3568920
J Nucl Med. 2013 Jan;54(1):27-32
pubmed: 23236018
Br J Cancer. 2009 Mar 10;100(5):693-700
pubmed: 19259091
Radiother Oncol. 2010 Sep;96(3):302-7
pubmed: 20708286
Contrast Media Mol Imaging. 2018 Dec 4;2018:9760492
pubmed: 30627062
Cancer. 2013 Feb 15;119(4):748-55
pubmed: 23011911
JAMA. 2008 Apr 23;299(16):1914-21
pubmed: 18430910
Cancer Radiother. 2010 Nov;14 Suppl 1:S120-6
pubmed: 21129654
J Clin Oncol. 1997 May;15(5):2040-9
pubmed: 9164216
Eur J Nucl Med Mol Imaging. 2012 Nov;39(11):1670-2
pubmed: 22968400
Am J Surg. 1984 Jan;147(1):43-8
pubmed: 6691550
Cancer. 2010 Sep 1;116(17):4007-13
pubmed: 20564111
Cancer. 1997 Dec 15;80(12 Suppl):2505-9
pubmed: 9406703
Radiother Oncol. 2019 Jul;136:21-28
pubmed: 31015125
Br J Cancer. 2011 Aug 9;105(4):498-504
pubmed: 21792197

Auteurs

Maelle Le Thiec (M)

Nuclear Medicine Unit, ICO Cancer Center, 44805 Saint Herblain, France.

Aude Testard (A)

Nuclear Medicine Unit, ICO Cancer Center, 49055 Angers, France.

Ludovic Ferrer (L)

Medical Physics Unit, ICO Cancer Center, 44805 Saint Herblain, France.
CRCINA, University of Nantes and Angers, INSERM UMR1232, CNRS-ERL6001, 49055 Angers, France.

Camille Guillerminet (C)

Medical Physics Unit, ICO Cancer Center, 49055 Angers, France.

Olivier Morel (O)

Nuclear Medicine Unit, ICO Cancer Center, 49055 Angers, France.

Bruno Maucherat (B)

Nuclear Medicine Unit, ICO Cancer Center, 44805 Saint Herblain, France.

Daniela Rusu (D)

Nuclear Medicine Unit, ICO Cancer Center, 44805 Saint Herblain, France.

Sylvie Girault (S)

Nuclear Medicine Unit, ICO Cancer Center, 49055 Angers, France.

Marie Lacombe (M)

Nuclear Medicine Unit, ICO Cancer Center, 49055 Angers, France.

Hadji Hamidou (H)

Radiation Oncology Unit, ICO Cancer Center, 49055 Angers, France.

Véronique Guérin Meyer (VG)

Medical Oncology Unit, ICO Cancer Center, 49055 Angers, France.

Emmanuel Rio (E)

Radiation Oncology Unit, ICO Cancer Center, 44805 Saint Herblain, France.

Sandrine Hiret (S)

Medical Oncology Unit, ICO Cancer Center, 44805 Saint Herblain, France.

Françoise Kraeber-Bodéré (F)

Nuclear Medicine Unit, ICO Cancer Center, 44805 Saint Herblain, France.
CRCINA, University of Nantes and Angers, INSERM UMR1232, CNRS-ERL6001, 49055 Angers, France.

Loïc Campion (L)

CRCINA, University of Nantes and Angers, INSERM UMR1232, CNRS-ERL6001, 49055 Angers, France.
Biometrics Unit, ICO Cancer Center, 44805 Saint Herblain, France.

Caroline Rousseau (C)

Nuclear Medicine Unit, ICO Cancer Center, 44805 Saint Herblain, France.
CRCINA, University of Nantes and Angers, INSERM UMR1232, CNRS-ERL6001, 49055 Angers, France.

Classifications MeSH